Facilitated By

San Antonio Medical Foundation

AN OPEN-LABEL, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL GROUP, MULTICENTRE PHASE 3 STUDY TO INVESTIGATE THE LONG TERM SAFETY, TOLERABILITY AND EFFICACY OF PA21 COMPARED WITH SEVELAMER CARBONATE IN DIALYSIS PATIENTS WITH

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Qunibi,Wajeh Y
Funded by
VIFOR PHARMA LTD.
Research Start Date
Status
Inactive
Clinical Care
Drug Discovery
Diabetes and Obesity